This research compilation was created in 2010 by Blue Cross and updated periodically using the MEDLINE database. The most recent literature update was performed through March 5, 2013.

At the time this policy was created, the literature consisted almost entirely of review articles describing the potential of stem-cell therapy for orthopedic applications in humans, along with basic science experiments on sources of mesenchymal stem cells (MSCs), regulation of cell growth and differentiation, and development of scaffolds. (3) Authors of these reviews indicated that the technology was in an early stage of development. In literature searches of the MEDLINE database, use of cultured MSCs in humans was identified in only a few centers in the U.S., Europe, and Asia. Since the policy was created, the evidence base has been steadily increasing, although nearly all of the studies to date have been performed outside of the U.S. and are retrospective comparisons.

### Cartilage Defects

In 2013, Filardo et al. conducted a systematic review of mesenchymal stem cells for the treatment of cartilage lesions. (4) They identified 72 preclinical papers and 18 clinical reports. Of the 18 clinical reports, none were randomized, 5 were comparative, 6 were case series, and 7 were case reports. In 2 clinical studies, the source of MSCs was adipose tissue, in 5, bone marrow concentrate, and in 11, the source was bone marrow-derived. Following is a summary of the key literature to date, focusing on comparative studies.

#### Cartilage Defects: MSCs Expanded from Bone Marrow

Wakitani and colleagues first reported use of expanded MSCs for repair of cartilage defects in 2002. (5) Cells from bone marrow aspirate of 12 patients with osteoarthritic knees were culture expanded, embedded in collagen gel, transplanted into the articular cartilage defect, and covered with autologous periosteum at the time of high tibial osteotomy. Clinical improvement was not found to be different between the experimental group and a group of 12 control patients who underwent high tibial osteotomy alone. Wakitani et al. have since published several cases of patients treated for isolated cartilage defects, with clinical improvement reported at up to 27 months. (6) However, most of the defects appear to have been filled with fibrocartilage. A 2011 report from Wakitani et al. was a follow-up safety study of 31 of the 41 patients (3 patients had died and 5 had undergone total knee arthroplasty) who had received MSCs for articular cartilage repair in their clinics between 1998 and 2008. (7) At a mean of 75 months (range, 5 to 137) since the index procedure, no tumors or infections were identified. Function was not reported.

Another study from Asia evaluated the efficacy of bone marrow-derived MSCs compared with autologous chondrocyte implantation (ACI) in 36 matched patient pairs. (8) Thirty-six consecutive patients with at least 1 symptomatic chondral lesion on the femoral condyle, trochlea, or patella were matched with 36 cases of ACI performed earlier, based on lesion sites and 10-year age intervals. Autologous MSCs were cultured from 30 mL of bone marrow from the iliac crest, tested to confirm that the cultured cells were MSCs, and implanted beneath a periosteal patch. Concomitant procedures included patella realignment, high-tibial osteotomy, partial meniscectomy, and anterior cruciate ligament reconstruction. Clinical outcomes, measured pre-operatively and at 3, 6, 12, 18, and 24 months’ after operation using the International Cartilage Repair Society (ICRS) Cartilage Injury Evaluation Package, showed improvement in patients’ scores over the 2-year follow-up in both groups, with no significant difference between groups.
for any of the outcome measures except for Physical Role Functioning on the Short Form (SF)-36, which showed a greater improvement over time in the MSC group.

A 2010 publication from Centeno et al. of Regenerative Sciences describes the use of percutaneously injected culture-expanded MSCs from the iliac spine in 226 patients. (9) Following harvesting, cells were cultured with autologous platelet lysate and re-injected under fluoroscopic guidance into peripheral joints (n=213) or intervertebral discs (n=13). Follow-up for adverse events at a mean of 10.6 months showed 10 cases of probable procedure-related complications (injections or stem-cell related), all of which were considered to be self-limited or treated with simple therapeutic measures. Serial magnetic resonance imageings (MRIs) from a subset of patients showed no evidence of tumor formation at a median follow-up of 15 months. The efficacy of these procedures was not reported. This procedure is no longer offered in the U.S.

**Cartilage Defects: MSCs Concentrated from Bone Marrow**

In 2009, Giannini et al. reported a one-step procedure for transplanting bone marrow-derived cells for type II (>1.5 cm², <5 mm deep) osteochondral lesions of the talus in 48 patients. (10) A total of 60 mL-bone marrow aspirate was collected from the iliac crest. The bone marrow-derived cells were concentrated in the operating room and implanted with a scaffold (collagen powder or hyaluronic acid membrane) and platelet gel. In a 2010 publication, Giannini et al. reported results of a retrospective analysis based on the evolution of the investigator’s technique at the time of treatment. Outcomes following arthroscopic application of the MSC concentrate (n=25) were similar to open (n=10) or arthroscopic (n=46) ACI. (11) ACI with a biodegradable scaffold is not commercially available in the U.S. (see policy No. 7.01.48).

**Cartilage Defects: Adipose-derived MSCs**

In 2012, Koh et al. reported a retrospective analysis of the injection of adipose-derived MSCs and platelet-rich plasma (PRP) into arthroscopically-debrided knees of 25 patients with osteoarthritis. (12) Results were compared with a randomly selected group of patients who had previously undergone arthroscopic debridement and PRP injections without stem cells. Although there was a trend for greater improvement in the MSC group, at final follow-up there was no significant difference between the MSC and control groups in clinical outcomes (Lysholm, Tegner, visual analog score). Use of PRP is discussed separately in policy No 2.01.16.

**Cartilage Defects: MSCs from Peripheral Blood**

A 2013 report from Asia described a small randomized controlled trial with autologous peripheral blood MSCs for focal articular cartilage lesions. (13) Fifty patients with grade 3 and 4 lesions of the knee joint underwent arthroscopic subchondral drilling followed by 5 weekly injections of hyaluronic acid. Half of the patients were randomly allocated to receive injections of peripheral blood stem cells or no further treatment. There were baseline differences in age between the groups, with a mean age of 38 years for the treatment group compared to 42 for the control group. The peripheral blood stem cells were harvested after stimulation with recombinant human granulocyte colony-stimulating factor, divided in vials, and cryopreserved. At 6 months after surgery, hyaluronic acid and MSC were re-administered over 3 weekly injections. At 18 months after surgery, second look arthroscopy on 16 patients in each group showed significantly higher histological scores (by about 10%) for the MSC group (1,066 vs. 957 by independent observers) while blinded evaluation of magnetic resonance imaging (MRI) showed a higher morphologic score (9.9 vs. 8.5). There was no difference in International Knee Documentation Committee (IKDC) scores between the 2 groups at 24 months after surgery. It is uncertain how differences in patient age at baseline may have affected the response to subchondral drilling.

**Cartilage Defects: Conclusions**
The evidence base on MSCs for cartilage repair is increasing, although as of March 2013 only one study was identified that was randomized. This small randomized study, which is limited by group differences in age at baseline, is also the only comparative study to show an improvement in histological and morphologic outcomes. No study to date has shown an improvement in functional outcomes following treatment with MSCs for cartilage repair.

**Fusion and Non-union**

There is limited evidence on the use of allografts with stem cells for fusion of the extremities or spine or for the treatment of non-union. One retrospective series from 2009 was identified on the use of Trinity Evolution Matrix MSC bone allograft for revision surgery of the foot and ankle. (14) Twenty-three patients were included who had undergone revision foot and/or ankle surgery for residual malunion, non-union, or significant segmental bone loss. Patients were followed to the point of radiographic and clinical union, which occurred at a median of 72.5 days for 21 of the 23 patients (91.3%).

**Osteonecrosis**

Two randomized comparative trials from Asia have been identified that evaluated the use of MSCs for osteonecrosis of the femoral head.

**Osteonecrosis: MSCs Expanded from Bone Marrow**

In 2012, Zhao et al. reported a randomized trial that included 100 patients (104 hips) with early stage femoral head osteonecrosis treated with core decompression and expanded bone marrow MSCs versus core decompression alone. (15) At 60 months after surgery, 2 of the 53 hips (3.7%) treated with MSCs progressed and underwent vascularized bone grafting, compared with 10 of 44 hips (23%) in the decompression group who progressed and underwent either vascularized bone grafting (n=5) or total hip replacement (n=5). The MSC group also had improved Harris Hip Scores compared with the control group on independent evaluation (data presented graphically). The volume of the lesion was also reduced by treatment with MSCs.

**Osteonecrosis: MSCs Concentrated from Bone Marrow**

Another small trial randomized 40 patients (51 hips) with early stage femoral head osteonecrosis to core decompression plus concentrated bone marrow MSCs or core decompression alone. (16) Blinding of assessments in this small trial was not described. Harris Hip Score was significantly improved in the MSC group (scores of 83.65 and 82.42) compared with core decompression (scores of 76.68 and 77.39). Kaplan-Meier analysis showed improved hip survival in the MSC group (mean of 51.9 weeks) compared to the core decompression group (mean of 46.7 weeks). There were no significant differences between the groups in the radiographic assessment or MRI results.

**Osteonecrosis: Conclusions**

Two small studies from Asia have compared core decompression alone versus core decompression with MSCs in patients with osteonecrosis of the femoral head. Both studies reported improvement in the Harris Hip Score in patients treated with MSCs, although it was not reported whether the patients or investigators were blinded to the treatment group. Hip survival was significantly improved following treatment with either expanded or concentrated MSCs. The effect appears to be larger with expanded MSCs compared to concentrated MSCs. Additional studies with a larger number of patients are needed to permit greater certainty regarding the effect of this treatment on health outcomes.

**Ongoing Clinical Trials**

TeleHealth Stem Cell Clinic (888) 828-4575 www.stemcelltherapyincalifornia.com
A search of online site: ClinicalTrials.gov in March 2013 identified a number of trials on use of MSCs for orthopedic indications from both within and outside the U.S. The following is a sample of some of the larger studies:

- A Phase I/II randomized, placebo controlled, double blind study of 2 doses of Chondrogen™ (Osiris Therapeutics) or a placebo intra-articular injection following meniscectomy in 60 patients is listed as completed in 2008 (NCT00225095). Chondrogen™ is a preparation of adult MSCs in a solution containing hyaluronic acid. Three-year follow-up of Chondrogen™ versus placebo injections is listed as a separate study (NCT00702741). The status of this trial is unknown.

- Medipost is sponsoring a randomized, open-label, multicenter Phase III clinical trial to compare the efficacy and safety of Cartistem® and microfracture in patients with knee articular cartilage injury or defect (NCT01041001). MSCs will be isolated from umbilical cord blood and cultured, mixed with semi-solid polymer, and administered in the cartilage tissue lesion by orthopedic surgery. The study is listed as completed as of April 2012 with an enrollment of 104 patients. Preliminary results of this study were presented at the annual meeting of the American Academy of Orthopaedic Surgeons in February 2012. As of March 2013, no peer-reviewed publications from this trial have been identified.

- Medipost is sponsoring a 60-month follow-up study (NCT01626677) of the patients who participated in the Phase III trial of Cartistem® (NCT01041001). The study has an estimated enrollment of 103 patients with completion in May 2015.

- NCT00885729 is a Phase I randomized, single-blind, active control trial of MSCs compared with chondrocytes to heal articular cartilage defects in 50 patients. The study is sponsored by an academic medical center in Norway. Both MSCs and chondrocytes will be delivered in a commercially available scaffold (not described). The estimated study completion date is 2018.

- The National University of Malaysia is sponsoring a randomized controlled trial of intra-articular MSC injection versus hyaluronic acid in patients with osteoarthritis (NCT01459640). The study has an estimated enrollment of 50 patients with completion in 2014.

- Three series are listed with Trinity Evolution Matrix for foot and ankle surgery, anterior cervical disectomy and fusion (ACDF), and posterior or transforaminal lumbar interbody fusion (PLIF or TLIF). All 3 studies are listed as ongoing but not recruiting subjects.

Summary

Overall, the literature suggests a technology that is at an early stage of development, with the vast majority of studies focused on development of methods for tissue engineering along with preliminary testing in animal models. Despite this research into the methods of treatment, there are uncertainties regarding the optimal source of cells and the delivery method. Current available evidence on procedures using autologous bone-marrow-derived mesenchymal stem cells (MSCs) for orthopedic indications in humans consists primarily of case series and small non-randomized comparative trials with insufficient data to evaluate health outcomes. In addition, expanded MSCs for orthopedic applications are not FDA approved (concentrated autologous MSCs do not require FDA approval). Due the lack of evidence that clinical outcomes are improved, use of stem cells for orthopedic applications is considered investigational.

References
